Bioxcel therapeutics to present updates from ongoing trial of bxcl701 in aggressive forms of prostate cancer at 2021 esmo congress

New haven, conn., sept. 12, 2021 (globe newswire) -- bioxcel therapeutics, inc. (“bioxcel” or the “company”) (nasdaq: btai), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing phase 1b/2 trial of bxcl701, the company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 european society for medical oncology (esmo) congress, which will take place virtually from september 16-21, 2021.
BTAI Ratings Summary
BTAI Quant Ranking